Evropská unie - čeština - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - ostatní dermatologické přípravky - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

Evropská unie - čeština - EMA (European Medicines Agency)

zoetis belgium sa - maleát oktakitinibu - přípravky proti dermatitidě, kromě kortikosteroidů - psi - - treatment of pruritus associated with allergic dermatitis in dogs. - treatment of clinical manifestations of atopic dermatitis in dogs.

Evropská unie - čeština - EMA (European Medicines Agency)

zoetis belgium sa - lokivetmab - jiné dermatologické přípravky, přípravky pro dermatitidu, s výjimkou kortikosteroidů - psi - léčba klinických projevů atopické dermatitidy u psů.

Evropská unie - čeština - EMA (European Medicines Agency)

leo pharma a/s - takrolimus - dermatitida, atopická - ostatní dermatologické přípravky - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. vyskytující se čtyři nebo více krát za rok), kteří měli počáteční reakci na maximálně šest týdnů léčby dvakrát denně takrolimus v masti (léze vymazána, téměř vymazány nebo mírně ovlivněny).

Evropská unie - čeština - EMA (European Medicines Agency)

pfizer europe ma eeig  - crisaborole - dermatitida, atopická - ostatní dermatologické přípravky - staquis je indikován k léčbě mírné až středně závažné atopické dermatitidy u dospělých a dětských pacientů od 2 let věku s ≤ 40% tělesného povrchu (bsa) ovlivněné.

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

viatris healthcare limited, dublin array - 15829 pimekrolimus - krém - 10mg/g - pimekrolimus

Evropská unie - čeština - EMA (European Medicines Agency)

almirall, s.a. - lebrikizumab - dermatitida, atopická - ostatní dermatologické přípravky - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.

Evropská unie - čeština - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - přípravky proti dermatitidě, kromě kortikosteroidů - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Evropská unie - čeština - EMA (European Medicines Agency)

pfizer europe ma eeig  - abrocitinib - dermatitida, atopická - ostatní dermatologické přípravky - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

Evropská unie - čeština - EMA (European Medicines Agency)

leo pharma a/s - tralokinumab - dermatitida, atopická - ostatní dermatologické přípravky - adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.